Astrazeneca Pharma India Ltd vs Jagsonpal Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8217 as of 30 Apr 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 618.18 crore. This represent the decline of -100% The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The ebitda of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 51.44 crore. This represent the decline of -100% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of 28.20% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Jagsonpal Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Jagsonpal Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of Jagsonpal Pharmaceuticals Ltd is 1,411 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Jagsonpal Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Jagsonpal Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Jagsonpal Pharmaceuticals Ltd?

As of May 3, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, Jagsonpal Pharmaceuticals Ltd stock price is INR ₹210.3.

How do dividend payouts of Astrazeneca Pharma India Ltd and Jagsonpal Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Jagsonpal Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.